FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Steven Grant

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Disorders

Leukemia

Procedures

Antineoplastic Combined Chemotherapy Protocols

Co-author Network

Publications

TOP 3
Beata Holkova; Connie Honeycutt; Maciej Kmieciak; Renee M McGovern; Edward Brent Perkins; Viswanathan Ramakrishnan; Joel M Reid; John D Roberts; Heidi Sankala; Geoffrey I Shapiro; Ellen Shrader; Jeffrey G Supko; Mary Beth Tombes; Martha D Wellons; John Wright; Matthew M Ames; Austin Doyle; Steven Grant
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Girija Dasmahapatra; Paul Dent; Richard I Fisher; Jonathan Friedberg; Hiral Patel; Steven Grant
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Mohamed Rahmani; David C Williams; Elisa Attkisson; Mandy Mayo Aust; Andrea Ferreira-Gonzalez; Steven Grant
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Steven Grant (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Beata Holkova; Connie Honeycutt; Maciej Kmieciak; Renee M McGovern; Edward Brent Perkins; Viswanathan Ramakrishnan; Joel M Reid; John D Roberts; Heidi Sankala; Geoffrey I Shapiro; Ellen Shrader; Jeffrey G Supko; Mary Beth Tombes; Martha D Wellons; John Wright; Matthew M Ames; Austin Doyle; Steven Grant
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(7):1873-83.
2013: Girija Dasmahapatra; Paul Dent; Richard I Fisher; Jonathan Friedberg; Hiral Patel; Steven Grant
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
British journal of haematology 2013;161(1):43-56.
2013: Mohamed Rahmani; David C Williams; Elisa Attkisson; Mandy Mayo Aust; Andrea Ferreira-Gonzalez; Steven Grant
Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Cancer research 2013;73(4):1340-51.
2013: Girija Dasmahapatra; Tri Nguyen; Hiral Patel; Elisa Attkisson; Steven Grant
PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(2):404-14.
2013: Kai Liu; Hardik I Parikh; Sarah Spiegel; Wenfang Xu; Jeremy C Allegood; Steven Grant; Tai L Guo; Nitai C Hait; Glen E Kellogg; Shijun Zhang
Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent.
PloS one 2013;8(2):e56471.
2012: Prithviraj Bose; Mohamed Rahmani; Steven Grant
Coordinate PI3K pathway and Bcl-2 family disruption in AML.
Oncotarget 2012;3(12):1499-500.
2012: Laurence Booth; Ching-Shih Chen; Nichola Cruickshanks; Steven Grant; Thomas Ridder; Paul Dent
OSU-03012 interacts with lapatinib to kill brain cancer cells.
Cancer biology & therapy 2012;13(14):1501-11.
2012: Nichola Cruickshanks; Steven Grant; Hossein Hamed; Yong Tang; Laurence Booth; Paul Dent
Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.
Molecular pharmacology 2012;82(6):1217-29.
2012: Alae Yaseen; Stefanie Hock; Roberto Rosato; Shuang Chen; Yun Dai; Paul Dent; Steven Grant
Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Molecular pharmacology 2012;82(6):1030-41.
2012: Prithviraj Bose; Steven Grant
Complementary combinations: what treatments will become key to the battle against acute myelogenous leukemia?
Expert review of hematology 2012;5(5):475-8.
2012: Shuang Chen; Yun Dai; Paul Dent; Mandy Garnett; Lora B Kramer; Dustin G Larsen; Jennifer Myers; Robert Z Orlowski; Xin-Yan Pei; Justin D Richey; Daniella M Schwartz; Gary L Simmons; Florence Su; Li Wang; Steven Grant
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Cancer research 2012;72(16):4225-37.
2012: Yong Tang; Yun Dai; Steven Grant; Hossein A Hamed; Andrew Poklepovic; Paul Dent
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Molecular pharmacology 2012;82(2):322-32.
2012: M Danielle Bareford; Nichola Cruickshanks; Jeremy C Allegood; Steven Grant; Hossein A Hamed; Besim Ogretmen; Margaret A Park; Andrew Poklepovic; Sarah Spiegel; Paul Dent
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
Cancer biology & therapy 2012;13(9):793-803.
2012: Beata Holkova; Steven Grant
Proteasome inhibitors in mantle cell lymphoma.
Best practice & research. Clinical haematology 2012;25(2):133-41.
2012: Prithviraj Bose; A Dimitrios Colevas; Brenda W Cooper; W Douglas Figg; Merrill J Egorin; Jan H Beumer; Connie Honeycut; Chiyo K Imamura; James W Jacobberger; Judith E Karp; Omer N Koc; Emmanouil Kontopodis; Selina M Luger; Edward B Perkins; John D Roberts; Tammy Stefan; Martha D Wellons; Steven Grant
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Cancer chemotherapy and pharmacology 2012;69(6):1657-67.
2012: Girija Dasmahapatra; Paul Dent; Richard I Fisher; Jonathan W Friedberg; Dmitry Lembersky; Hiral Patel; Derick Peterson; Minkyeong P Son; Elisa Attkisson; Steven Grant
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
Molecular cancer therapeutics 2012;11(5):1122-32.
2012: Yong Tang; Gary Tye; Adly Yacoub; Steven Grant; Hossein A Hamed; Andrew Poklepovic; Paul Dent
Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
Cancer biology & therapy 2012;13(7):567-74.
2012: Nichola Cruickshanks; M Danielle Bareford; Paul B Fisher; Steven Grant; Hossein A Hamed; Andrew Poklepovic; Paul Dent
Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
Molecular pharmacology 2012;81(5):748-58.
2012: Belal Azab; Sujit K Bhutia; David T Curiel; Swadesh K Das; Rupesh Dash; Paul Dent; Igor P Dmitriev; Steven Grant; Michael Hedvat; Maurizio Pellecchia; Bridget A Quinn; John C Reed; Devanand Sarkar; Siddik Sarkar; Xue-Ning Shen; Xiang-Yang Wang; Paul B Fisher
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) in combination with the Apogossypol derivative BI-97C1 (Sabutoclax) improves therapeutic efficacy in low CAR colorectal cancer cells.
Journal of cellular physiology 2012;227(5):2145-53.
2012: Sujit K Bhutia; David T Curiel; Swadesh K Das; Rupesh Dash; Paul Dent; Steven Grant; Timothy P Kegelman; Seok-Geun Lee; Federica Rizzi; Devanand Sarkar; Zhao-Zhong Su; Xiang-Yang Wang; Belal Azab; Saverio Bettuzzi; Paul B Fisher
mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer.
Journal of cellular physiology 2012;227(5):1805-13.
2012: Yong Tang; Steven Grant; Yun Dai; Paul Dent
Enhancing CHK1 inhibitor lethality in glioblastoma.
Cancer biology & therapy 2012;13(6):379-88.
2012: Yong Tang; Nichola Cruickshanks; Paul B Fisher; Steven Grant; Hossein A Hamed; Paul Dent
Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.
Molecular pharmacology 2012;81(4):527-40.
2012: Roberto Rosato; Stefanie Hock; Yun Dai; Paul Dent; Steven Grant
LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.
Leukemia research 2012;36(4):491-8.
2012: Laurence Booth; Sophie C Cazanave; Ching-Shih Chen; Steven Grant; Hossein A Hamed; Besim Ogretmen; Adly Yacoub; Paul Dent
OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing.
Cancer biology & therapy 2012;13(4):224-36.
2012: Steven Grant; Yun Dai
Histone deacetylase inhibitors and rational combination therapies.
Advances in cancer research 2012;116():199-237.
2012: Hisashi Harada; Steven Grant
Targeting the regulatory machinery of BIM for cancer therapy.
Critical reviews in eukaryotic gene expression 2012;22(2):117-29.
2012: Kai Liu; Hardik Parikh; Wei Rao; Steven Grant; Tai L Guo; Glen E Kellogg; Qianbin Li; Shijun Zhang
3,5-Disubstituted-thiazolidine-2,4-dione analogs as anticancer agents: design, synthesis and biological characterization.
European journal of medicinal chemistry 2012;47(1):125-37.
2011: Xin-Yan Pei; Yukie Takabatake; Leena E Youssefian; Lora B Kramer; Jorge A Almenara; Wesley W Bodie; Shuang Chen; Yun Dai; Paul Dent; Jessica Felthousen; Steven Grant
Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Blood 2011;118(19):5189-200.
2011: Beata Holkova; Steven Grant
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies.
Expert review of hematology 2011;4(5):483-6.
2011: Bridget A Quinn; Mohamed Rahmani; John C Reed; Devanand Sarkar; Siddik Sarkar; John L Stebbins; Jun Wei; Bainan Wu; Belal Azab; David T Curiel; Swadesh K Das; Santanu Dasgupta; Rupesh Dash; Paul Dent; Igor Dmitriev; Steven Grant; Michael Hedvat; Sachin Kumar; Regina A Oyesanya; Maurizio Pellecchia; Paul B Fisher
Targeting Mcl-1 for the therapy of cancer.
Expert opinion on investigational drugs 2011;20(10):1397-411.
2011: M Danielle Bareford; Matthew E Burow; Nichola Cruickshanks; Paul B Fisher; Steven Grant; Hossein A Hamed; Richard G Moran; Kenneth P Nephew; Yong Tang; Paul Dent
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Autophagy 2011;7(10):1261-2.
2011: Mark Andrew Dickson; Mithat Gonen; Steven Grant; Robert A Lefkowitz; Renee M McGovern; Dana E Rathkopf; Joel M Reid; John D Roberts; Matthew M Ames; Lauren M Cane; Richard Carvajal; Heather J Dials; Gary K Schwartz
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
Investigational new drugs 2011;29(5):1004-12.
2011: Yun Dai; Paul Dent; Vanessa L Funk; Lora B Kramer; Xin-Yan Pei; Li Wang; Shuang Chen; Steven Grant
Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.
The Journal of biological chemistry 2011;286(39):34036-50.
2011: Steven Grant
Targeting Waldenstrom macroglobulinemia with histone deacetylase inhibitors.
Leukemia & lymphoma 2011;52(9):1623-5.
2011: Qifang Zhang; Masoud Manjili; Kazuya Shimoda; Jamie L Sturgill; Karol Szczepanek; Harry Bear; Shuang Chen; Joanna Cichy; Daniel Conrad; Yun Dai; Marta Derecka; Ana M Gamero; Laura J Graham; Steven Grant; Maciej Kmieciak; Catherine Koebel; Andrew C Larner
The role of Tyk2 in regulation of breast cancer growth.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2011;31(9):671-7.
2011: Girija Dasmahapatra; Paul Dent; Richard I Fisher; Jonathan W Friedberg; Dmitry Lembersky; Minkyeong P Son; Elisa Attkisson; Steven Grant
Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo.
Molecular cancer therapeutics 2011;10(9):1686-97.
2011: Rupesh Dash; Belal Azab; Bridget A Quinn; Xuening Shen; Xiang-Yang Wang; Swadesh K Das; Mohamed Rahmani; Jun Wei; Michael Hedvat; Paul Dent; Igor P Dmitriev; David T Curiel; Steven Grant; Bainan Wu; John L Stebbins; Maurizio Pellecchia; John C Reed; Devanand Sarkar; Paul B Fisher
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(21):8785-90.
2011: Beata Holkova; Loveleen Kang; Sarah Kolla; Cody Peer; E Brent Perkins; Viswanathan Ramakrishnan; John D Roberts; G David Roodman; Ellen Shrader; Robert K Stuart; Daniel M Sullivan; Neha Talreja; Mary Beth Tombes; Martha D Wellons; John Wright; Domenico Coppola; Jana Lynn Dawson; Austin Doyle; William D Figg; Kevin T Hogan; Steven Grant
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(10):3388-97.
2011: Paul Dent; Yong Tang; Adly Yacoub; Yun Dai; Paul B Fisher; Steven Grant
CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.
Molecular interventions 2011;11(2):133-40.
2011: Steven Grant
Enhancing proteotoxic stress as an anticancer strategy.
Oncotarget 2011;2(4):284-6.
2011: Yun Dai; Paul Dent; Lora B Kramer; Xin-Yan Pei; Li Wang; Shuang Chen; Steven Grant
Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
British journal of haematology 2011;153(2):222-35.
2011: Margaret A Park; Hossein A Hamed; Clint Mitchell; Nichola Cruickshanks; Rupesh Dash; Jeremy C Allegood; Igor P Dmitriev; Gary Tye; Besim Ogretmen; Sarah Spiegel; Adly Yacoub; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.
Molecular pharmacology 2011;79(3):368-80.
2011: Yun Dai; Shuang Chen; Rena Shah; Xin-Yan Pei; Li Wang; Jorge A Almenara; Lora B Kramer; Paul Dent; Steven Grant
Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Blood 2011;117(6):1947-57.
2011: Yun Dai; Steven Grant
Methods to study cancer therapeutic drugs that target cell cycle checkpoints.
Methods in molecular biology (Clifton, N.J.) 2011;782():257-304.
2011: Rupesh Dash; Belal Azab; Xue-Ning Shen; Upneet K Sokhi; Siddik Sarkar; Zhao-zhong Su; Xiang-Yang Wang; Pier Paolo Claudio; Paul Dent; Igor P Dmitriev; David T Curiel; Steven Grant; Devanand Sarkar; Paul B Fisher
Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic.
Discovery medicine 2011;11(56):46-56.
2010: Mohamed Rahmani; Mandy Mayo; Rupesh Dash; Upneet Kaur Sokhi; Igor P Dmitriev; Devanand Sarkar; Paul Dent; David T Curiel; Paul B Fisher; Steven Grant
Melanoma differentiation associated gene-7/interleukin-24 potently induces apoptosis in human myeloid leukemia cells through a process regulated by endoplasmic reticulum stress.
Molecular pharmacology 2010;78(6):1096-104.
2010: Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Xiang-Yang Wang; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zao-Zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej S Lesniak; Steven Grant; David T Curiel; Paul B Fisher
The development of MDA-7/IL-24 as a cancer therapeutic.
Pharmacology & therapeutics 2010;128(2):375-84.
2010: Rupesh Dash; Sujit K Bhutia; Belal Azab; Zao-Zhong Su; Bridget A Quinn; Timothy P Kegelmen; Swadesh K Das; Keetae Kim; Seok-Geun Lee; Margaret A Park; Adly Yacoub; Mohammed Rahmani; Luni Emdad; Igor P Dmitriev; Xiang-Yang Wang; Devanand Sarkar; Steven Grant; Paul Dent; David T Curiel; Paul B Fisher
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity.
Cytokine & growth factor reviews 2010;21(5):381-91.
2010: Yun Dai; Monica L Guzman; Shuang Chen; Li Wang; Sin-Kei Yeung; Xin-Yan Pei; Paul Dent; Craig T Jordan; Steven Grant
The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.
British journal of haematology 2010;151(1):70-83.
2010: Paul Dent; Adly Yacoub; Hossein A Hamed; Margaret A Park; Rupesh Dash; Sujit K Bhutia; Devanand Sarkar; Pankaj Gupta; Luni Emdad; Irina V Lebedeva; Moira Sauane; Zao-Zhong Su; Mohamed Rahmani; William C Broaddus; Harold F Young; Maciej Lesniak; Steven Grant; David T Curiel; Paul B Fisher
MDA-7/IL-24 as a cancer therapeutic: from bench to bedside.
Anti-cancer drugs 2010;21(8):725-31.
2010: Margaret A Park; Roland Reinehr; Dieter Häussinger; Christina Voelkel Johnson; Besim Ogretmen; Adly Yacoub; Steven Grant; Paul Dent
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Molecular cancer therapeutics 2010;9(8):2220-31.
2010: Qianbin Li; Jingde Wu; Hui Zheng; Kai Liu; Tai L Guo; Yuying Liu; Scott T Eblen; Steven Grant; Shijun Zhang
Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.
Bioorganic & medicinal chemistry letters 2010;20(15):4526-30.
2010: Steven Grant
HDAC inhibitors repress the polycomb protein BMI1.
Cell cycle (Georgetown, Tex.) 2010;9(14):2705-6.
2010: Girija Dasmahapatra; Dmitry Lembersky; Lora Kramer; Richard I Fisher; Jonathan Friedberg; Paul Dent; Steven Grant
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
Blood 2010;115(22):4478-87.
2010: Hossein A Hamed; Adly Yacoub; Margaret A Park; Patrick J Eulitt; Rupesh Dash; Devanand Sarkar; Igor P Dmitriev; Maciej S Lesniak; Khalid Shah; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
Inhibition of multiple protective signaling pathways and Ad.5/3 delivery enhances mda-7/IL-24 therapy of malignant glioma.
Molecular therapy : the journal of the American Society of Gene Therapy 2010;18(6):1130-42.
2010: Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Mohamed Rahmani; Dieter Häussinger; Roland Reinehr; Christina Voelkel Johnson; Paul B Fisher; Steven Grant; Paul Dent
17-allylamino-17-demethoxygeldanamycin and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and reactive oxygen species.
Molecular cancer therapeutics 2010;9(5):1378-95.
2010: Sujit K Bhutia; Rupesh Dash; Swadesh K Das; Belal Azab; Zao-Zhong Su; Seok-Geun Lee; Steven Grant; Adly Yacoub; Paul Dent; David T Curiel; Devanand Sarkar; Paul B Fisher
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24.
Cancer research 2010;70(9):3667-76.
2010: Hossein A Hamed; Adly Yacoub; Margaret A Park; Patrick Eulitt; Devanand Sarkar; Igor P Dimitrie; Ching-Shih Chen; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
OSU-03012 enhances Ad.7-induced GBM cell killing via ER stress and autophagy and by decreasing expression of mitochondrial protective proteins.
Cancer biology & therapy 2010;9(7):526-36.
2010: Yun Dai; Steven Grant
Targeting Chk1 in the replicative stress response.
Cell cycle (Georgetown, Tex.) 2010;9(6):1025.
2010: Tri K Nguyen; Nicholas Jordan; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.
Leukemia research 2010;34(3):379-86.
2010: Adly Yacoub; Hossein A Hamed; Jeremy C Allegood; Clint Mitchell; Sarah Spiegel; Maciej S Lesniak; Besim Ogretmen; Rupesh Dash; Devanand Sarkar; William C Broaddus; Steven Grant; David T Curiel; Paul B Fisher; Paul Dent
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells.
Cancer research 2010;70(3):1120-9.
2010: Adly Yacoub; Renyan Liu; Margaret A Park; Hossein A Hamed; Rupesh Dash; Danielle N Schramm; Devanand Sarkar; Igor P Dimitriev; Jessica K Bell; Steven Grant; Nicholas P Farrell; David T Curiel; Paul B Fisher; Paul Dent
Cisplatin enhances protein kinase R-like endoplasmic reticulum kinase- and CD95-dependent melanoma differentiation-associated gene-7/interleukin-24-induced killing in ovarian carcinoma cells.
Molecular pharmacology 2010;77(2):298-310.
2010: Yun Dai; Steven Grant
New insights into checkpoint kinase 1 in the DNA damage response signaling network.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):376-83.
2009: Paul Dent; David T Curiel; Steven Grant; Paul B Fisher
Minting a new class of polo-like-kinase inhibitors.
Cancer biology & therapy 2009;8(24):2384-5.
2009: Steven Grant
New agents for AML and MDS.
Best practice & research. Clinical haematology 2009;22(4):501-7.
2009: Steven Grant
Targeting histone demethylases in cancer therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(23):7111-3.
2009: Shuang Chen; Yun Dai; Xin-Yan Pei; Steven Grant
Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
Molecular and cellular biology 2009;29(23):6149-69.
2009: Aditi Pandya Martin; Clint Mitchell; Mohamed Rahmani; Kenneth P Nephew; Steven Grant; Paul Dent
Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
Cancer biology & therapy 2009;8(21):2084-96.
2009: Qianbin Li; Adnan Al-Ayoubi; Tailiang Guo; Hui Zheng; Aurijit Sarkar; Tri Nguyen; Scott T Eblen; Steven Grant; Glen E Kellogg; Shijun Zhang
Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.
Bioorganic & medicinal chemistry letters 2009;19(21):6042-6.
2009: A A Rambal; Z L G Panaguiton; Lora Kramer; Steven Grant; H Harada
MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.
Leukemia 2009;23(10):1744-54.
2009: Aditi Pandya Martin; Margaret A Park; Clint Mitchell; Teneille Walker; Mohamed Rahmani; Andrew Thorburn; Dieter Häussinger; Roland Reinehr; Steven Grant; Paul Dent
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Molecular pharmacology 2009;76(2):327-41.
2009: Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Martin Graf; Mohamed Rahmani; Peter J Houghton; Christina Voelkel Johnson; Steven Grant; Paul Dent
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Molecular pharmacology 2009;76(2):342-55.
2009: Paul Dent; David T Curiel; Paul B Fisher; Steven Grant
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2009;12(3):65-73.
2009: Margaret A Park; Teneille Walker; Aditi Pandya Martin; Jeremy C Allegood; Nicollaq Vozhilla; Luni Emdad; Devanand Sarkar; Mohamed Rahmani; Martin Graf; Adly Yacoub; Constantinos Koumenis; Sarah Spiegel; David T Curiel; Christina Voelkel Johnson; Steven Grant; Paul B Fisher; Paul Dent
MDA-7/IL-24-induced cell killing in malignant renal carcinoma cells occurs by a ceramide/CD95/PERK-dependent mechanism.
Molecular cancer therapeutics 2009;8(5):1280-91.
2009: Girija Dasmahapatra; Dmitry Lembersky; Mohamed Rahmani; Lora Kramer; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Bcl-2 antagonists interact synergistically with bortezomib in DLBCL cells in association with JNK activation and induction of ER stress.
Cancer biology & therapy 2009;8(9):808-19.
2009: Paul Dent; Steven Grant; Paul B Fisher; David T Curiel
PI3K: A rational target for ovarian cancer therapy?
Cancer biology & therapy 2009;8(1):27-30.
2008: Steven Grant
Is the focus moving toward a combination of targeted drugs?
Best practice & research. Clinical haematology 2008;21(4):629-37.
2008: Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Stefanie Coe; Peter Atadja; Paul Dent; Steven Grant
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions.
Molecular cancer therapeutics 2008;7(10):3285-97.
2008: Margaret A Park; Guo Zhang; Aditi Pandya Martin; Hossein Hamed; Clint Mitchell; Phillip B Hylemon; Martin Graf; Mohamed Rahmani; Kevin Ryan; Xiang Liu; Sarah Spiegel; James Norris; Paul B Fisher; Steven Grant; Paul Dent
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
Cancer biology & therapy 2008;7(10):1648-62.
2008: Margaret A Park; Guo Zhang; James Norris; Phillip B Hylemon; Paul B Fisher; Steven Grant; Paul Dent
Regulation of autophagy by ceramide-CD95-PERK signaling.
Autophagy 2008;4(7):929-31.
2008: Yun Dai; Shuang Chen; Xin-Yan Pei; Jorge A Almenara; Lora B Kramer; Charis A Venditti; Paul Dent; Steven Grant
Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Blood 2008;112(6):2439-49.
2008: Guo Zhang; Margaret A Park; Clint Mitchell; Teneille Walker; Hossein Hamed; Elaine Studer; Martin Graf; Mohamed Rahmani; Seema Gupta; Phillip B Hylemon; Paul B Fisher; Steven Grant; Paul Dent
Multiple cyclin kinase inhibitors promote bile acid-induced apoptosis and autophagy in primary hepatocytes via p53-CD95-dependent signaling.
The Journal of biological chemistry 2008;283(36):24343-58.
2008: Margaret A Park; Guo Zhang; Clint Mitchell; Mohamed Rahmani; Hossein Hamed; Michael P Hagan; Adly Yacoub; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95.
Molecular cancer therapeutics 2008;7(9):2633-48.
2008: Guo Zhang; Margaret A Park; Clint Mitchell; Hossein Hamed; Mohamed Rahmani; Aditi Pandya Martin; David T Curiel; Adly Yacoub; Martin Graf; Ray Lee; John D Roberts; Paul B Fisher; Steven Grant; Paul Dent
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5385-99.
2008: Steven Grant
Cotargeting survival signaling pathways in cancer.
The Journal of clinical investigation 2008;118(9):3003-6.
2008: Paul Dent; Adly Yacoub; Margaret Park; Devanand Sarkar; Khalid Shah; David T Curiel; Steven Grant; Paul B Fisher
Searching for a cure: gene therapy for glioblastoma.
Cancer biology & therapy 2008;7(9):1335-40.
2008: Aditi Pandya Martin; Anna Miller; Luni Emad; Mohamed Rahmani; Teneille Walker; Clint Mitchell; Michael P Hagan; Margaret A Park; Adly Yacoub; Paul B Fisher; Steven Grant; Paul Dent
Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
Molecular pharmacology 2008;74(3):807-22.
2008: Steven W Paugh; Barbara S Paugh; Mohamed Rahmani; Dmitri Kapitonov; Jorge A Almenara; Tomasz Kordula; Sheldon Milstien; Jeffrey K Adams; Robert E Zipkin; Steven Grant; Sarah Spiegel
A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia.
Blood 2008;112(4):1382-91.
2008: Yun Dai; Shuang Chen; Charis A Venditti; Xin-Yan Pei; Tri K Nguyen; Paul Dent; Steven Grant
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Blood 2008;112(3):793-804.
2008: Adly Yacoub; Hossein Hamed; Luni Emdad; Wagner Dos Santos; Pankaj Gupta; William C Broaddus; Viswanathan Ramakrishnan; Devanand Sarkar; Khalid Shah; David T Curiel; Steven Grant; Paul B Fisher; Paul Dent
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors.
Cancer biology & therapy 2008;7(6):917-33.
2008: Margaret A Park; Adly Yacoub; Devanand Sarkar; Luni Emdad; Mohamed Rahmani; Sarah Spiegel; Constantinos Koumenis; Martin Graf; David T Curiel; Steven Grant; Paul B Fisher; Paul Dent
PERK-dependent regulation of MDA-7/IL-24-induced autophagy in primary human glioma cells.
Autophagy 2008;4(4):513-5.
2008: Hossein Hamed; Clint Mitchell; Margaret A Park; David Hanna; Aditi Pandya Martin; Benjamin Harrison; William Hawkins; David A Curiel; Paul B Fisher; Steven Grant; Adly Yacoub; Michael P Hagan; Paul Dent
Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo.
Cancer biology & therapy 2008;7(4):587-93.
2008: Margaret A Park; David T Curiel; Constantinos Koumenis; Martin Graf; Ching-Shih Chen; Paul B Fisher; Steven Grant; Paul Dent
PERK-dependent regulation of HSP70 expression and the regulation of autophagy.
Autophagy 2008;4(3):364-7.
2008: Margaret A Park; Adly Yacoub; Mohamed Rahmani; Guo Zhang; Lori Hart; Michael P Hagan; Stuart K Calderwood; Michael Y Sherman; Constantinos Koumenis; Sarah Spiegel; Ching-Shih Chen; Martin Graf; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.
Molecular pharmacology 2008;73(4):1168-84.
2008: Hossein Hamed; William Hawkins; Clint Mitchell; Donna Gilfor; Guo Zhang; Xin-Yan Pei; Yun Dai; Michael P Hagan; John D Roberts; Adly Yacoub; Steven Grant; Paul Dent
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.
Molecular cancer therapeutics 2008;7(3):616-29.
2008: Adly Yacoub; Pankaj Gupta; Margaret A Park; Mohammed Rhamani; Hossein Hamed; David Hanna; Guo Zhang; Devanand Sarkar; Irina Lebedeva; Luni Emdad; Constantinos Koumenis; David T Curiel; Steven Grant; Paul B Fisher; Paul Dent
Regulation of GST-MDA-7 toxicity in human glioblastoma cells by ERBB1, ERK1/2, PI3K, and JNK1-3 pathway signaling.
Molecular cancer therapeutics 2008;7(2):314-29.
2008: Adly Yacoub; Margaret A Park; Pankaj Gupta; Mohamed Rahmani; Guo Zhang; Hossein Hamed; David Hanna; Devanand Sarkar; Irina Lebedeva; Luni Emdad; Moira Sauane; Nicollaq Vozhilla; Sarah Spiegel; Constantinos Koumenis; Martin Graf; David T Curiel; Steven Grant; Paul B Fisher; Paul Dent
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells.
Molecular cancer therapeutics 2008;7(2):297-313.
2008: Yun Dai; Shuang Chen; Lora B Kramer; Vanessa L Funk; Paul Dent; Steven Grant
Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):549-58.
2007: Clint Mitchell; Margaret A Park; Guo Zhang; Adly Yacoub; David T Curiel; Paul B Fisher; John D Roberts; Steven Grant; Paul Dent
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
Molecular cancer therapeutics 2007;6(12 Pt 1):3101-12.
2007: Roberto R Rosato; Jorge A Almenara; Stefanie Coe; Steven Grant
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Cancer research 2007;67(19):9490-500.
2007: Xin-Yan Pei; Yun Dai; Sarah Tenorio; Jianghua Lu; Hisashi Harada; Paul Dent; Steven Grant
MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
Blood 2007;110(6):2092-101.
2007: Mohamed Rahmani; Tri K Nguyen; Paul Dent; Steven Grant
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Molecular pharmacology 2007;72(3):788-95.
2007: Clint Mitchell; Peyman Kabolizadeh; John Ryan; John D Roberts; Adly Yacoub; David T Curiel; Paul B Fisher; Michael P Hagan; Nicholas Farrell; Steven Grant; Paul Dent
Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling.
Molecular pharmacology 2007;72(3):704-14.
2007: Mohamed Rahmani; Eric Maynard Davis; Timothy Ryan Crabtree; Joseph Reza Habibi; Tri K Nguyen; Paul Dent; Steven Grant
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
Molecular and cellular biology 2007;27(15):5499-513.
2007: Girija Dasmahapatra; Nitin Yerram; Yun Dai; Paul Dent; Steven Grant
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(14):4280-90.
2007: Steven Grant; Paul Dent
Simultaneous interruption of signal transduction and cell cycle regulatory pathways: implications for new approaches to the treatment of childhood leukemias.
Current drug targets 2007;8(6):751-9.
2007: Yun Dai; Payal Khanna; Shuang Chen; Xin-Yan Pei; Paul Dent; Steven Grant
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
Blood 2007;109(10):4415-23.
2007: Tri K Nguyen; Mohamed Rahmani; Hisashi Harada; Paul Dent; Steven Grant
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Blood 2007;109(9):4006-15.
2007: Yun Dai; Steven Grant
Targeting multiple arms of the apoptotic regulatory machinery.
Cancer research 2007;67(7):2908-11.
2007: Youwen Fang; Elaine Studer; Clint Mitchell; Steven Grant; William M Pandak; Phillip B Hylemon; Paul Dent
Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Galphai signaling.
Molecular pharmacology 2007;71(4):1122-8.
2007: Kristoffer Valerie; Adly Yacoub; Michael P Hagan; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Radiation-induced cell signaling: inside-out and outside-in.
Molecular cancer therapeutics 2007;6(3):789-801.
2007: Roberto R Rosato; Jorge A Almenara; Sarah S Kolla; Sonia C Maggio; Stefanie Coe; Maria S Giménez; Paul Dent; Steven Grant
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Molecular cancer therapeutics 2007;6(2):692-702.
2007: Clint Mitchell; Margaret A Park; Guo Zhang; Song Iy Han; Hisashi Harada; Richard A Franklin; Adly Yacoub; Pin-Lan Li; Phillip B Hylemon; Steven Grant; Paul Dent
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines.
Molecular cancer therapeutics 2007;6(2):618-32.
2007: Shuang Chen; Yun Dai; Hisashi Harada; Paul Dent; Steven Grant
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Cancer research 2007;67(2):782-91.
2007: Paul Dent; Philip B Hylemon; Steven Grant; Paul B Fisher
Approaches for monitoring signal transduction changes in normal and cancer cells.
Methods in molecular biology (Clifton, N.J.) 2007;383():259-76.
2007: Adly Yacoub; William Hawkins; David Hanna; Hong Young; Margaret A Park; Mark Grant; John D Roberts; David T Curiel; Paul B Fisher; Kristoffer Valerie; Steven Grant; Michael P Hagan; Paul Dent
Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.
Molecular pharmacology 2007;71(1):259-75.
2006: Adly Yacoub; Anna Miller; Ruben Caron; Liang Qiao; David A Curiel; Paul B Fisher; Michael P Hagan; Steven Grant; Paul Dent
Radiotherapy-induced signal transduction.
Endocrine-related cancer 2006;13 Suppl 1():S99-114.
2006: Xin-Yan Pei; Weiqun Li; Yun Dai; Paul Dent; Steven Grant
Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Molecular pharmacology 2006;70(6):1965-73.
2006: John D Roberts; Mitchell R Smith; Eric J Feldman; Louise Cragg; Michael Millenson; Gail J Roboz; Connie Honeycutt; Rose Thune; Kristin Padavic-Shaller; W Hans Carter; Viswanathan Ramakrishnan; Anthony J Murgo; Steven Grant
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5809-16.
2006: Adly Yacoub; Donna Gilfor; William Hawkins; Margaret A Park; David Hanna; Michael P Hagan; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
MEK1/2 inhibition promotes Taxotere lethality in mammary tumors in vivo.
Cancer biology & therapy 2006;5(10):1332-9.
2006: Girija Dasmahapatra; Tri K Nguyen; Paul Dent; Steven Grant
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl.
Leukemia research 2006;30(10):1263-72.
2006: Wentao Jia; Venkatesh Hegde; Narendra P Singh; Daniel Sisco; Steven Grant; Mitzi Nagarkatti; Prakash S Nagarkatti
Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria.
Molecular cancer research : MCR 2006;4(8):549-62.
2006: Ning Gao; Lora Kramer; Mohamed Rahmani; Paul Dent; Steven Grant
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism.
Molecular pharmacology 2006;70(2):645-55.
2006: Adly Yacoub; Margaret A Park; David Hanna; Young Hong; Clint Mitchell; Aditi P Pandya; Hisashi Harada; Garth Powis; Ching-Shih Chen; Constantinos Koumenis; Steven Grant; Paul Dent
OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Molecular pharmacology 2006;70(2):589-603.
2006: Tri K Nguyen; Mohamed Rahmani; Ning Gao; Lora Kramer; Amie S Corbin; Brian J Druker; Paul Dent; Steven Grant
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2239-47.
2006: Yun Dai; Steven Grant
CDK inhibitor targets: a hit or miss proposition?: cyclin-dependent kinase inhibitors kill tumor cells by downregulation of anti-apoptotic proteins.
Cancer biology & therapy 2006;5(2):171-3.
2006: Yun Dai; Tracy E Hamm; Paul Dent; Steven Grant
Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry.
Cell cycle (Georgetown, Tex.) 2006;5(4):437-46.
2006: Girija Dasmahapatra; Jorge A Almenara; Steven Grant
Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2.
Molecular pharmacology 2006;69(1):288-98.
2006: Roberto R Rosato; Sonia C Maggio; Jorge A Almenara; Shawn G Payne; Peter Atadja; Sarah Spiegel; Paul Dent; Steven Grant
The histone deacetylase inhibitor LAQ824 induces human leukemia cell death through a process involving XIAP down-regulation, oxidative injury, and the acid sphingomyelinase-dependent generation of ceramide.
Molecular pharmacology 2006;69(1):216-25.
2006: Girija Dasmahapatra; Mohamed Rahmani; Paul Dent; Steven Grant
The tyrphostin adaphostin interacts synergistically with proteasome inhibitors to induce apoptosis in human leukemia cells through a reactive oxygen species (ROS)-dependent mechanism.
Blood 2006;107(1):232-40.
2006: Ning Gao; Mohamed Rahmani; Xianglin Shi; Paul Dent; Steven Grant
Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress.
Blood 2006;107(1):241-9.
2005: Paul Dent; Song Iy Han; Clint Mitchell; Elaine Studer; Adly Yacoub; Jennifer Rubin Grandis; Steven Grant; Geoffrey W Krystal; Phillip B Hylemon
Inhibition of insulin/IGF-1 receptor signaling enhances bile acid toxicity in primary hepatocytes.
Biochemical pharmacology 2005;70(11):1685-96.
2005: William Hawkins; Clint Mitchell; Robert McKinstry; Donna Gilfor; James Starkey; Yun Dai; Kathy Dawson; Viswanathan Ramakrishnan; John D Roberts; Adly Yacoub; Steven Grant; Paul Dent
Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth.
Cancer biology & therapy 2005;4(11):1275-84.
2005: Roberto R Rosato; Jorge A Almenara; Sonia C Maggio; Peter Atadja; Ruth Craig; Julie Vrana; Paul Dent; Steven Grant
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Molecular cancer therapeutics 2005;4(11):1772-85.
2005: Mohamed Rahmani; Eric Maynard Davis; Cheryl Bauer; Paul Dent; Steven Grant
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
The Journal of biological chemistry 2005;280(42):35217-27.
2005: Chunrong Yu; Girija Dasmahapatra; Paul Dent; Steven Grant
Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells.
Leukemia 2005;19(9):1579-89.
2005: Roberto R Rosato; Steven Grant
Histone deacetylase inhibitors: insights into mechanisms of lethality.
Expert opinion on therapeutic targets 2005;9(4):809-24.
2005: Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Molecular and cellular biology 2005;25(13):5429-44.
2005: Paul Dent; Adly Yacoub; Steven Grant; David T Curiel; Paul B Fisher
MDA-7/IL-24 regulates proliferation, invasion and tumor cell radiosensitivity: a new cancer therapy?
Journal of cellular biochemistry 2005;95(4):712-9.
2005: Xin-Yan Pei; Yun Dai; Mohamed Rahmani; Weiqun Li; Paul Dent; Steven Grant
The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4589-600.
2005: Ning Gao; Mohamed Rahmani; Paul Dent; Steven Grant
2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process.
Oncogene 2005;24(23):3797-809.
2005: Paul Dent; Adly Yacoub; Steven Grant
DMC: novel celecoxib derivatives to rap cancer.
Cancer biology & therapy 2005;4(5):583-4.
2005: Mohamed Rahmani; Erin Reese; Yun Dai; Cheryl Bauer; Lora B Kramer; Mei Huang; Richard Jove; Paul Dent; Steven Grant
Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.
Molecular pharmacology 2005;67(4):1166-76.
2005: Mohamed Rahmani; Erin Reese; Yun Dai; Cheryl Bauer; Shawn G Payne; Paul Dent; Sarah Spiegel; Steven Grant
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Cancer research 2005;65(6):2422-32.
2005: Michael Hahn; Weiqun Li; Chunrong Yu; Mohamed Rahmani; Paul Dent; Steven Grant
Rapamycin and UCN-01 synergistically induce apoptosis in human leukemia cells through a process that is regulated by the Raf-1/MEK/ERK, Akt, and JNK signal transduction pathways.
Molecular cancer therapeutics 2005;4(3):457-70.
2005: Rubén W Carón; Adly Yacoub; Clint Mitchell; Xiaoyu Zhu; Young Hong; Takehiko Sasazuki; Senji Shirasawa; Michael P Hagan; Steven Grant; Paul Dent
Radiation-stimulated ERK1/2 and JNK1/2 signaling can promote cell cycle progression in human colon cancer cells.
Cell cycle (Georgetown, Tex.) 2005;4(3):456-64.
2005: Yun Dai; Mohamed Rahmani; Xin-Yan Pei; Payal Khanna; Song Iy Han; Clint Mitchell; Paul Dent; Steven Grant
Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
Blood 2005;105(4):1706-16.
2005: Rubén W Carón; Adly Yacoub; Min Li; Xiaoyu Zhu; Clint Mitchell; Young Hong; William Hawkins; Takehiko Sasazuki; Senji Shirasawa; Alan P Kozikowski; Philip A Dennis; Michael P Hagan; Steven Grant; Paul Dent
Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival.
Molecular cancer therapeutics 2005;4(2):257-70.
2005: Rubén W Carón; Adly Yacoub; Xiaoyu Zhu; Clint Mitchell; Song Iy Han; Takehiko Sasazuki; Senji Shirasawa; Michael P Hagan; Steven Grant; Paul Dent
H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
Molecular cancer therapeutics 2005;4(2):243-55.
2004: Xin-Yan Pei; Yun Dai; Steven Grant
The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.
Molecular cancer therapeutics 2004;3(12):1513-24.
2004: L Andrew Bouton; Carlos D Ramirez; Daniel P Bailey; C Fitzhugh Yeatman; Joyce Yue; Harry V Wright; Jos Domen; Roberto R Rosato; Steven Grant; Krista Fischer-Stenger; John J Ryan
Costimulation with interleukin-4 and interleukin-10 induces mast cell apoptosis and cell-cycle arrest: the role of p53 and the mitochondrion.
Experimental hematology 2004;32(12):1137-45.
2004: Steven Grant
The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
Leukemia 2004;18(12):1931-3.
2004: Paul Dent; Steven Grant
Irofulven: resurgence for alkylating therapy in cancer?
Cancer biology & therapy 2004;3(11):1143-4.
2004: Roberto R Rosato; Yun Dai; Jorge A Almenara; Sonia C Maggio; Steven Grant
Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Leukemia 2004;18(11):1780-8.
2004: Wesam Ahmed; Mohamed Rahmani; Paul Dent; Steven Grant
The cyclin-dependent kinase inhibitor p21(CIP1/WAF1) blocks paclitaxel-induced G2M arrest and attenuates mitochondrial injury and apoptosis in p53-null human leukemia cells.
Cell cycle (Georgetown, Tex.) 2004;3(10):1305-11.
2004: Youwen Fang; Song Iy Han; Clint Mitchell; Seema Gupta; Elaine Studer; Steven Grant; Phillip B Hylemon; Paul Dent
Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes.
Hepatology (Baltimore, Md.) 2004;40(4):961-71.
2004: Ning Gao; Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Molecular pharmacology 2004;66(4):956-63.
2004: Yun Dai; Mohamed Rahmani; Seth J Corey; Paul Dent; Steven Grant
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
The Journal of biological chemistry 2004;279(33):34227-39.
2004: Adly Yacoub; Clint Mitchell; Young Hong; Rahul V Gopalkrishnan; Zao-Zhong Su; Pankaj Gupta; Moria Sauane; Irina Lebedeva; David T Curiel; Parameshwar J Mahasreshti; Myrna R Rosenfeld; William C Broaddus; C David James; Steven Grant; Paul B Fisher; Paul Dent
MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells.
Cancer biology & therapy 2004;3(8):739-51.
2004: Yun Dai; Mohamed Rahmani; Xin-Yan Pei; Paul Dent; Steven Grant
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Blood 2004;104(2):509-18.
2004: Steven Grant; Paul Dent
Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?
Molecular cancer therapeutics 2004;3(7):873-5.
2004: Xin-Yan Pei; Yun Dai; Steven Grant
Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3839-52.
2004: Chunrong Yu; Mohamed Rahmani; Paul Dent; Steven Grant
The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib.
Experimental cell research 2004;295(2):555-66.
2004: Sonia C Maggio; Roberto R Rosato; Lora B Kramer; Yun Dai; Mohamed Rahmani; David S Paik; Ann C Czarnik; Shawn G Payne; Sarah Spiegel; Steven Grant
The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.
Cancer research 2004;64(7):2590-600.
2004: Yun Dai; Xin-Yan Pei; Mohamed Rahmani; Daniel H Conrad; Paul Dent; Steven Grant
Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.
Blood 2004;103(7):2761-70.
2004: Steven Grant; Paul Dent
Activation of MAP kinase pathways by TRAIL: don't expect the obvious.
Cancer biology & therapy 2004;3(3):302-4.
2004: Roberto R Rosato; Jorge A Almenara; Chunrong Yu; Steven Grant
Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol.
Molecular pharmacology 2004;65(3):571-81.
2004: Yun Dai; Steven Grant
Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents.
Current oncology reports 2004;6(2):123-30.
2004: Chunrong Yu; Mohamed Rahmani; Jorge A Almenara; Edward A Sausville; Paul Dent; Steven Grant
Induction of apoptosis in human leukemia cells by the tyrosine kinase inhibitor adaphostin proceeds through a RAF-1/MEK/ERK- and AKT-dependent process.
Oncogene 2004;23(7):1364-76.
2004: Song Iy Han; Elaine Studer; Seema Gupta; Youwen Fang; Liang Qiao; Weiqun Li; Steven Grant; Phillip B Hylemon; Paul Dent
Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes.
Hepatology (Baltimore, Md.) 2004;39(2):456-63.
2004: Roberto R Rosato; Steven Grant
Histone deacetylase inhibitors in clinical development.
Expert opinion on investigational drugs 2004;13(1):21-38.
2003: Roberto R Rosato; Jorge A Almenara; Yun Dai; Steven Grant
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.
Molecular cancer therapeutics 2003;2(12):1273-84.
2003: Mohamed Rahmani; Chunrong Yu; Yun Dai; Erin Reese; Wesam Ahmed; Paul Dent; Steven Grant
Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
Cancer research 2003;63(23):8420-7.
2003: Yun Dai; Paul Dent; Steven Grant
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL.
Molecular pharmacology 2003;64(6):1402-9.
2003: Chunrong Yu; Mohamed Rahmani; Daniel Conrad; Mark Subler; Paul Dent; Steven Grant
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Blood 2003;102(10):3765-74.
2003: Adly Yacoub; Song Iy Han; Ruben Caron; Donna Gilfor; Susan Mooberry; Steven Grant; Paul Dent
Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro.
Cancer biology & therapy 2003;2(6):670-6.
2003: Yun Dai; Mohamed Rahmani; Steven Grant
Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process.
Oncogene 2003;22(46):7108-22.
2003: Julie Litz; Patricia Carlson; G Sakuntala Warshamana-Greene; Steven Grant; Geoffrey W Krystal
Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4586-94.
2003: Xin-Yan Pei; Yun Dai; Steven Grant
The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Leukemia 2003;17(10):2036-45.
2003: Mohamed Rahmani; Chunrong Yu; Erin Reese; Wesam Ahmed; Karen Hirsch; Paul Dent; Steven Grant
Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21(CIP1/WAF1) induction rather than AKT inhibition.
Oncogene 2003;22(40):6231-42.
2003: Chunrong Yu; Mark Subler; Mohamed Rahmani; Erin Reese; Geoffrey W Krystal; Daniel Conrad; Paul Dent; Steven Grant
Induction of apoptosis in BCR/ABL+ cells by histone deacetylase inhibitors involves reciprocal effects on the RAF/MEK/ERK and JNK pathways.
Cancer biology & therapy 2003;2(5):544-51.
2003: Yun Dai; Mohamed Rahmani; Steven Grant
An intact NF-kappaB pathway is required for histone deacetylase inhibitor-induced G1 arrest and maturation in U937 human myeloid leukemia cells.
Cell cycle (Georgetown, Tex.) 2003;2(5):467-72.
2003: Paul Dent; Adly Yacoub; Paul B Fisher; Michael P Hagan; Steven Grant
MAPK pathways in radiation responses.
Oncogene 2003;22(37):5885-96.
2003: Wentao Jia; Chunrong Yu; Mohamed Rahmani; Geoffrey W Krystal; Edward A Sausville; Paul Dent; Steven Grant
Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways.
Blood 2003;102(5):1824-32.
2003: Adly Yacoub; Clint Mitchell; Andrea Lister; Irina Lebedeva; Devanand Sarkar; Zao-Zhong Su; Carter Sigmon; Robert McKinstry; Viswanathan Ramakrishnan; Liang Qiao; William C Broaddus; Rahul V Gopalkrishnan; Steven Grant; Paul B Fisher; Paul Dent
Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(9):3272-81.
2003: Yun Dai; Steven Grant
Cyclin-dependent kinase inhibitors.
Current opinion in pharmacology 2003;3(4):362-70.
2003: Adly Yacoub; Clint Mitchell; Irina Lebedeva; Devanand Sarkar; Zao-Zhong Su; Robert McKinstry; Rahul V Gopalkrishnan; Steven Grant; Paul B Fisher; Paul Dent
mda-7 (IL-24) Inhibits growth and enhances radiosensitivity of glioma cells in vitro via JNK signaling.
Cancer biology & therapy 2003;2(4):347-53.
2003: Adly Yacoub; Clint Mitchell; Jessica Brannon; Elizabeth Rosenberg; Liang Qiao; Robert McKinstry; W Marston Linehan; Zao-shong Su; Devanand Sarkar; Irina Lebedeva; Kristoffer Valerie; Rahul V Gopalkrishnan; Steven Grant; Paul B Fisher; Paul Dent
MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity.
Molecular cancer therapeutics 2003;2(7):623-32.
2003: Roberto R Rosato; Jorge A Almenara; Steven Grant
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Cancer research 2003;63(13):3637-45.
2003: Roy H Decker; JAY LEVIN; Lora B Kramer; Yun Dai; Steven Grant
Enforced expression of the tumor suppressor p53 renders human leukemia cells (U937) more sensitive to 1-[beta-D-arabinofuranosyl]cytosine (ara-C)-induced apoptosis.
Biochemical pharmacology 2003;65(12):1997-2008.
2003: Hisashi Harada; Steven Grant
Apoptosis regulators.
Reviews in clinical and experimental hematology 2003;7(2):117-38.
2003: Chunrong Yu; Mohamed Rahmani; Jorge A Almenara; Mark Subler; Geoffrey W Krystal; Daniel Conrad; Lubya Varticovski; Paul Dent; Steven Grant
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Cancer research 2003;63(9):2118-26.
2003: Liang Qiao; Song Iy Han; Youwen Fang; Jong Sung Park; Seema Gupta; Donna Gilfor; George P Amorino; Kristoffer Valerie; Linda Sealy; John F Engelhardt; Steven Grant; Phillip B Hylemon; Paul Dent
Bile acid regulation of C/EBPbeta, CREB, and c-Jun function, via the extracellular signal-regulated kinase and c-Jun NH2-terminal kinase pathways, modulates the apoptotic response of hepatocytes.
Molecular and cellular biology 2003;23(9):3052-66.
2003: Shujie Wang; Zhiliang Wang; Paul Dent; Steven Grant
Induction of tumor necrosis factor by bryostatin 1 is involved in synergistic interactions with paclitaxel in human myeloid leukemia cells.
Blood 2003;101(9):3648-57.
2003: Chunrong Yu; Mohamed Rahmani; Yun Dai; Daniel Conrad; Geoffrey W Krystal; Paul Dent; Steven Grant
The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Cancer research 2003;63(8):1822-33.
2003: J Kevin Leach; Liang Qiao; Youwen Fang; Song L Y Han; Donna Gilfor; Paul B Fisher; Steven Grant; Phillip B Hylemon; Darrell Peterson; Paul Dent
Regulation of p21 and p27 expression by the hepatitis B virus X protein and the alternate initiation site X proteins, AUG2 and AUG3.
Journal of gastroenterology and hepatology 2003;18(4):376-85.
2003: Paul Dent; Adly Yacoub; Joseph N Contessa; Ruben Caron; George P Amorino; Kristoffer Valerie; Michael P Hagan; Steven Grant; Rupert K Schmidt-Ullrich
Stress and radiation-induced activation of multiple intracellular signaling pathways.
Radiation research 2003;159(3):283-300.
2003: Steven Grant; John D Roberts
The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2003;6(1):15-26.
2003: Paul Dent; Liang Qiao; Donna Gilfor; Michael J Birrer; Steven Grant; Paul B Fisher
The regulation of tumor suppressor genes by oncogenes.
Methods in molecular biology (Clifton, N.J.) 2003;222():269-92.
2003: Roberto R Rosato; Steven Grant
Histone deacetylase inhibitors in cancer therapy.
Cancer biology & therapy 2003;2(1):30-7.
2003: Leanne Cartee; Sonia C Maggio; Rebecca Smith; Heidi Sankala; Paul Dent; Steven Grant
Protein kinase C-dependent activation of the tumor necrosis factor receptor-mediated extrinsic cell death pathway underlies enhanced apoptosis in human myeloid leukemia cells exposed to bryostatin 1 and flavopiridol.
Molecular cancer therapeutics 2003;2(1):83-93.
2003: Shujie Wang; Zhiliang Wang; Steven Grant
Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.
Molecular pharmacology 2003;63(1):232-42.
2002: John D Roberts; Mitchell R Smith; Eric J Feldman; Louise Cragg; Steven Grant
Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.
Clinical lymphoma 2002;3(3):184-8.
2002: Chunrong Yu; Yun Dai; Paul Dent; Steven Grant
Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Cancer biology & therapy 2002;1(6):674-82.
2002: Steven Grant; Paul Dent
Conversion of drug-induced differentiation to apoptosis by pharmacologic cyclin-dependent kinase inhibitors.
Cell cycle (Georgetown, Tex.) 2002;1(6):383-8.
2002: Yun Dai; Terry Landowski; Steven T Rosen; Paul Dent; Steven Grant
Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Blood 2002;100(9):3333-43.
2002: Chunrong Yu; Geoffrey W Krystal; Paul Dent; Steven Grant
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(9):2976-84.
2002: Leanne Cartee; Heidi Sankala; Christine Davis; Rebecca Smith; Sonia C Maggio; Peck-Sun Lin; Paul Dent; Steven Grant
7-hydroxystaurosporine (UCN-01) and ionizing radiation combine to inhibit the growth of Bcl-2-overexpressing U937 leukemia cells through a non-apoptotic mechanism.
International journal of oncology 2002;21(2):351-9.
2002: Robert J McKallip; Catherine Lombard; Michael Fisher; Billy R Martin; Seongho Ryu; Steven Grant; Prakash S Nagarkatti; Mitzi Nagarkatti
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.
Blood 2002;100(2):627-34.
2002: Mohamed Rahmani; Steven Grant
UCN-01 (7-hydroxystauorsporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937).
Cell cycle (Georgetown, Tex.) 2002;1(4):273-81.
2002: Louise Cragg; Michael Andreeff; Eric Feldman; John Roberts; Anthony J Murgo; Mary Winning; Mary Beth Tombes; Gail J Roboz; Lora Kramer; Steven Grant
Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2123-33.
2002: Jorge A Almenara; Roberto R Rosato; Steven Grant
Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).
Leukemia 2002;16(7):1331-43.
2002: Liang Qiao; Robert McKinstry; Seema Gupta; Donna Gilfor; Jolene J Windle; Phillip B Hylemon; Steven Grant; Paul B Fisher; Paul Dent
Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53.
Hepatology (Baltimore, Md.) 2002;36(1):39-48.
2002: Mohamed Rahmani; Yun Dai; Steven Grant
The histone deacetylase inhibitor sodium butyrate interacts synergistically with phorbol myristate acetate (PMA) to induce mitochondrial damage and apoptosis in human myeloid leukemia cells through a tumor necrosis factor-alpha-mediated process.
Experimental cell research 2002;277(1):31-47.
2002: Leanne Cartee; Rebecca Smith; Yun Dai; Mohamed Rahmani; Roberto R Rosato; Jorge A Almenara; Paul Dent; Steven Grant
Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.
Molecular pharmacology 2002;61(6):1313-21.
2002: Robert McKinstry; Liang Qiao; Adly Yacoub; Yun Dai; Roy H Decker; Shawn Holt; Michael P Hagan; Steven Grant; Paul Dent
Inhibitors of MEK1/2 interact with UCN-01 to induce apoptosis and reduce colony formation in mammary and prostate carcinoma cells.
Cancer biology & therapy 2002;1(3):243-53.
2002: Zhiliang Wang; Shujie Wang; Yun Dai; Steven Grant
Bryostatin 1 increases 1-beta-D-arabinofuranosylcytosine-induced cytochrome c release and apoptosis in human leukemia cells ectopically expressing Bcl-x(L).
The Journal of pharmacology and experimental therapeutics 2002;301(2):568-77.
2002: Liang Qiao; Adly Yacoub; Elaine Studer; Seema Gupta; Xin-Yan Pei; Steven Grant; Phillip B Hylemon; Paul Dent
Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes.
Hepatology (Baltimore, Md.) 2002;35(4):779-89.
2002: Yun Dai; Paul Dent; Steven Grant
Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A.
Cell cycle (Georgetown, Tex.) 2002;1(2):143-52.
2002: Liang Qiao; Adly Yacoub; Robert McKinstry; Jong Sung Park; Ruben Caron; Paul B Fisher; Michael P Hagan; Steven Grant; Paul Dent
Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms.
Cancer biology & therapy 2002;1(2):168-76.
2002: Roy H Decker; Shujie Wang; Yun Dai; Paul Dent; Steven Grant
Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis.
Cancer biology & therapy 2002;1(2):136-44.
2002: Steven Grant; Sarah Spiegel
A chicken-or-egg conundrum in apoptosis: which comes first? Ceramide or PKCdelta?
The Journal of clinical investigation 2002;109(6):717-9.
2002: Roberto R Rosato; Jorge A Almenara; Leanne Cartee; Vicki Betts; Srikumar Chellappan; Steven Grant
The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.
Molecular cancer therapeutics 2002;1(4):253-66.
2002: Steven Grant; Liang Qiao; Paul Dent
Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival.
Frontiers in bioscience : a journal and virtual library 2002;7():d376-89.
2002: Steven Grant; Paul B Fisher; Paul Dent
The role of signal transduction pathways in drug and radiation resistance.
Cancer treatment and research 2002;112():89-108.
2002: Chunrong Yu; Geoffrey Krystal; Lyuba Varticovksi; Robert McKinstry; Mohamed Rahmani; Paul Dent; Steven Grant
Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Cancer research 2002;62(1):188-99.
2001: Liang Qiao; K Leach; Robert McKinstry; Donna Gilfor; Adly Yacoub; Jong Sung Park; Steven Grant; Phillip B Hylemon; Paul B Fisher; Paul Dent
Hepatitis B virus X protein increases expression of p21(Cip-1/WAF1/MDA6) and p27(Kip-1) in primary mouse hepatocytes, leading to reduced cell cycle progression.
Hepatology (Baltimore, Md.) 2001;34(5):906-17.
2001: Dania Rabah; Steven Grant; Check Ma; Daniel H Conrad
Bryostatin-1 specifically inhibits in vitro IgE synthesis.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(9):4910-8.
2001: Chunrong Yu; Zhiliang Wang; Paul Dent; Steven Grant
MEK1/2 inhibitors promote Ara-C-induced apoptosis but not loss of Deltapsi(m) in HL-60 cells.
Biochemical and biophysical research communications 2001;286(5):1011-8.
2001: Liang Qiao; Elaine Studer; K Leach; Robert McKinstry; Seema Gupta; Roy H Decker; R Kukreja; Kristoffer Valerie; Prakash S Nagarkatti; Wafik S El-Deiry; J Molkentin; Rupert K Schmidt-Ullrich; Paul B Fisher; Steven Grant; Phillip B Hylemon; Paul Dent
Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis.
Molecular biology of the cell 2001;12(9):2629-45.
2001: Roy H Decker; Yun Dai; Steven Grant
The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway.
Cell death and differentiation 2001;8(7):715-24.
2001: Yun Dai; C Yu; V Singh; L Tang; Z Wang; R McInistry; Paul Dent; Steven Grant
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Cancer research 2001;61(13):5106-15.
2001: Roberto R Rosato; Zhiliang Wang; Rahul V Gopalkrishnan; Paul B Fisher; Steven Grant
Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).
International journal of oncology 2001;19(1):181-91.
2001: Chunrong Yu; Shujie Wang; Paul Dent; Steven Grant
Sequence-dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitors of the mitogen-activated protein kinase kinase/mitogen-activated protein kinase pathway.
Molecular pharmacology 2001;60(1):143-54.
2001: Jong Sung Park; Liang Qiao; Zao-Zhong Su; Darin Hinman; Karen A Willoughby; Robert McKinstry; Adly Yacoub; Gregory J Duigou; C S H Young; Steven Grant; Michael P Hagan; E Ellis; Paul B Fisher; Paul Dent
Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways.
Oncogene 2001;20(25):3266-80.
2001: Paul Dent; Steven Grant
Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):775-83.
2001: Julie Vrana; Steven Grant
Synergistic induction of apoptosis in human leukemia cells (U937) exposed to bryostatin 1 and the proteasome inhibitor lactacystin involves dysregulation of the PKC/MAPK cascade.
Blood 2001;97(7):2105-14.
2001: Leanne Cartee; Zhiliang Wang; Roy H Decker; Srikumar Chellappan; Gina Fusaro; K G Hirsch; Heidi Sankala; Paul Dent; Steven Grant
The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.
Cancer research 2001;61(6):2583-91.
2001: S Harvey; Roy H Decker; Yun Dai; G Schaefer; L Tang; Lora Kramer; Paul Dent; Steven Grant
Interactions between 2-fluoroadenine 9-beta-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):320-30.
2000: L Tang; Lawrence Boise; Paul Dent; Steven Grant
Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).
Biochemical pharmacology 2000;60(10):1445-56.
2000: C Bondzi; Steven Grant; Geoffrey W Krystal
A novel assay for the measurement of Raf-1 kinase activity.
Oncogene 2000;19(43):5030-3.
2000: Leanne Cartee; C Davis; Peck-Sun Lin; Steven Grant
Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism.
International journal of radiation biology 2000;76(10):1323-33.
2000: Zhiliang Wang; Shujie Wang; Paul B Fisher; Paul Dent; Steven Grant
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-beta-D-arabinofuranosylcytosine.
Differentiation; research in biological diversity 2000;66(1):1-13.
2000: Rupert K Schmidt-Ullrich; Paul Dent; Steven Grant; Ross B Mikkelsen; Kristoffer Valerie
Signal transduction and cellular radiation responses.
Radiation research 2000;153(3):245-57.
2000: Leanne Cartee; Julie Vrana; Zhiliang Wang; Jong Sung Park; Michael J Birrer; Paul B Fisher; Steven Grant; Paul Dent
Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway.
International journal of oncology 2000;16(2):413-22.
2000: John D Roberts; EA Poplin; Mary Beth Tombes; B Kyle; Darcy Spicer; Steven Grant; T Synold; Richard G Moran
Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
Cancer chemotherapy and pharmacology 2000;45(2):103-10.
1999: Y X Schwarz; M y Yang; D Qin; Jiuhua Wu; W D Jarvis; Steven Grant; GREGORY BURTON; Andras K Szakal; John G Tew
Follicular dendritic cells protect malignant B cells from apoptosis induced by anti-Fas and antineoplastic agents.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(12):6442-7.
1999: Julie Vrana; Roy H Decker; Charlene R Johnson; Zhiliang Wang; W David Jarvis; V M Richon; M Ehinger; Paul B Fisher; Steven Grant
Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53.
Oncogene 1999;18(50):7016-25.
1999: Carole A Oskeritzian; Z Wang; JP Kochan; Margaret M Grimes; Z Du; Hyeun Wook Chang; Steven Grant; Lawrence B Schwartz
Recombinant human (rh)IL-4-mediated apoptosis and recombinant human IL-6-mediated protection of recombinant human stem cell factor-dependent human mast cells derived from cord blood mononuclear cell progenitors.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(9):5105-15.
1999: Robert M Tombes; Ross B Mikkelsen; W D Jarvis; Steven Grant
Downregulation of delta CaM kinase II in human tumor cells.
Biochimica et biophysica acta 1999;1452(1):1-11.
1999: Shujie Wang; Zhiliang Wang; Lawrence Boise; Paul Dent; Steven Grant
Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL.
Leukemia 1999;13(10):1564-73.
1999: W David Jarvis; Charlene R Johnson; FA Fornari; Jong Sung Park; Paul Dent; Steven Grant
Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation.
The Journal of pharmacology and experimental therapeutics 1999;290(3):1384-92.
1999: Julie Vrana; Lora B Kramer; A M Saunders; X F Zhang; Paul Dent; L F Povirk; Steven Grant
Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
Biochemical pharmacology 1999;58(1):121-31.
1999: Julie Vrana; Zhiliang Wang; A S Rao; L Tang; J H Chen; Lora B Kramer; Steven Grant
Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1.
Leukemia 1999;13(7):1046-55.
1999: Shujie Wang; Zhiliang Wang; Lawrence Boise; Paul Dent; Steven Grant
Loss of the bcl-2 phosphorylation loop domain increases resistance of human leukemia cells (U937) to paclitaxel-mediated mitochondrial dysfunction and apoptosis.
Biochemical and biophysical research communications 1999;259(1):67-72.
1999: Julie Vrana; Steven Grant; Paul Dent
Inhibition of the MAPK pathway abrogates BCL2-mediated survival of leukemia cells after exposure to low-dose ionizing radiation.
Radiation research 1999;151(5):559-69.
1999: Zhiliang Wang; GC Van Tuyle; Daniel Conrad; Paul B Fisher; Paul Dent; Steven Grant
Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.
Cancer research 1999;59(6):1259-67.
1999: W David Jarvis; Steven Grant
Protein kinase C targeting in antineoplastic treatment strategies.
Investigational new drugs 1999;17(3):227-40.
1999: EA Poplin; John Roberts; M Tombs; Steven Grant; E Rubin
Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.
Investigational new drugs 1999;17(1):57-62.
1998: Paul Dent; W D Jarvis; Michael J Birrer; Paul B Fisher; R K Schmidt-Ullrich; Steven Grant
The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity.
Leukemia 1998;12(12):1843-50.
1998: W David Jarvis; Steven Grant
The role of ceramide in the cellular response to cytotoxic agents.
Current opinion in oncology 1998;10(6):552-9.
1998: W David Jarvis; FA Fornari; Robert M Tombes; R K Erukulla; R Bittman; Gary K Schwartz; Paul Dent; Steven Grant
Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-beta-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signaling.
Molecular pharmacology 1998;54(5):844-56.
1998: Zhiliang Wang; Z Z Su; Paul B Fisher; Shujie Wang; G VanTuyle; Steven Grant
Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentation in human myelomonocytic leukemia cells.
Experimental cell research 1998;244(1):105-16.
1998: Shujie Wang; C Y Guo; A Castillo; Paul Dent; Steven Grant
Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937).
Biochemical pharmacology 1998;56(5):635-44.
1998: Julie Vrana; A M Saunders; Srikumar Chellappan; Steven Grant
Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937).
Differentiation; research in biological diversity 1998;63(1):33-42.
1998: Julie Vrana; A S Rao; Zhiliang Wang; W David Jarvis; Steven Grant
Effects of bryostatin 1 and calcium ionophore (A23187) on apoptosis and differentiation in human myeloid leukemia cells (HL-60) following 1-beta-D-arabinofuranosylcytosine exposure.
International journal of oncology 1998;12(4):927-34.
1998: Steven Grant; John Roberts; EA Poplin; Mary Beth Tombes; B Kyle; D Welch; M Carr; Harry D Bear
Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(3):611-8.
1998: Steven Grant
Ara-C: cellular and molecular pharmacology.
Advances in cancer research 1998;72():197-233.
1997: W David Jarvis; FA Fornari; KL Auer; AJ Freemerman; E Szabo; Michael J Birrer; Charlene R Johnson; S E Barbour; Paul Dent; Steven Grant
Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine.
Molecular pharmacology 1997;52(6):935-47.
1997: Shujie Wang; Julie Vrana; T M Bartimole; AJ Freemerman; W David Jarvis; Lora B Kramer; Geoffrey W Krystal; Paul Dent; Steven Grant
Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
Molecular pharmacology 1997;52(6):1000-9.
1997: J Chelliah; AJ Freemerman; S Wu-Pong; W David Jarvis; Steven Grant
Potentiation of ara-C-induced apoptosis by the protein kinase C activator bryostatin 1 in human leukemia cells (HL-60) involves a process dependent upon c-Myc.
Biochemical pharmacology 1997;54(5):563-73.
1997: W David Jarvis; KL Auer; M Spector; George Kunos; Steven Grant; P Hylemon; Ross B Mikkelsen; Paul Dent
Positive and negative regulation of JNK1 by protein kinase C and p42(MAP kinase) in adult rat hepatocytes.
FEBS letters 1997;412(1):9-14.
1997: T M Bartimole; Julie Vrana; AJ Freemerman; W David Jarvis; J C Reed; Lawrence Boise; Steven Grant
Modulation of the expression of Bcl-2 and related proteins in human leukemia cells by protein kinase C activators: relationship to effects on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis.
Cell death and differentiation 1997;4(4):294-303.
1997: AJ Freemerman; Julie Vrana; Robert M Tombes; H Jiang; Srikumar Chellappan; Paul B Fisher; Steven Grant
Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60).
Leukemia 1997;11(4):504-13.
1996: Steven Grant; A J Turner; AJ Freemerman; Zhiliang Wang; L Kramer; W David Jarvis
Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Experimental cell research 1996;228(1):65-75.
1996: A S Rao; AJ Freemerman; W David Jarvis; J Chelliah; H D Bear; Ross B Mikkelsen; Steven Grant
Effect of AS101 on bryostatin 1-mediated differentiation induction, cell cycle arrest, and modulation of drug-induced apoptosis in human myeloid leukemia cells.
Leukemia 1996;10(7):1150-8.
1996: Harry D Bear; A W McFadden; P J Kostuchenko; K A Lipshy; GG Hamad; A J Turner; J D Roberts; M Carr; S Carr; Steven Grant
Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration.
Anti-cancer drugs 1996;7(3):299-306.
1996: Steven Grant; AJ Freemerman; Michael J Birrer; H A Martin; A J Turner; E Szabo; J Chelliah; W David Jarvis
Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67).
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(5):603-13.
1996: AJ Freemerman; A J Turner; Michael J Birrer; E Szabo; K Valerie; Steven Grant
Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C.
Molecular pharmacology 1996;49(5):788-95.
1996: FA Fornari; D W Jarvis; Steven Grant; MS Orr; JK Randolph; F K White; David Gewirtz
Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin.
Biochemical pharmacology 1996;51(7):931-40.
1996: W David Jarvis; FA Fornari; R S Traylor; H A Martin; Lora B Kramer; R K Erukulla; Robert Bittman; Steven Grant
Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells.
The Journal of biological chemistry 1996;271(14):8275-84.
1996: Marcel Verheij; R Bose; X H Lin; B Yao; W David Jarvis; Steven Grant; Michael J Birrer; E Szabo; L I Zon; J M Kyriakis; Adriana Haimovitz-Friedman; Zvi Fuks; Richard Kolesnick
Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis.
Nature 1996;380(6569):75-9.
1996: N C Watson; W David Jarvis; MS Orr; Steven Grant; David Gewirtz
Radiosensitization of HL-60 human leukaemia cells by bryostatin-1 in the absence of increased DNA fragmentation or apoptotic cell death.
International journal of radiation biology 1996;69(2):183-92.
1995: Steven Grant; A Turner; P Nelms; Saul Yanovich
Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D-arabinofuranosylcytosine.
Leukemia 1995;9(5):808-14.
1995: Steven Grant; AJ Freemerman; Patricia C Gregory; H A Martin; A J Turner; Ross B Mikkelsen; J Chelliah; Saul Yanovich; W David Jarvis
Induction of apoptotic DNA fragmentation and c-jun downregulation in human myeloid leukemia cells by the permeant Ca2+ chelator BAPTA/AM.
Oncology research 1995;7(7-8):381-92.
1994: W David Jarvis; FA Fornari; J L Browning; David Gewirtz; Richard Kolesnick; Steven Grant
Attenuation of ceramide-induced apoptosis by diglyceride in human myeloid leukemia cells.
The Journal of biological chemistry 1994;269(50):31685-92.
1994: S J Sung; Peck-Sun Lin; Rupert K Schmidt-Ullrich; C E Hall; J A Walters; C McCrady; Steven Grant
Effects of the protein kinase C stimulant bryostatin 1 on the proliferation and colony formation of irradiated human T-lymphocytes.
International journal of radiation biology 1994;66(6):775-83.
1994: FA Fornari; W David Jarvis; Steven Grant; MS Orr; JK Randolph; F K White; V R Mumaw; E T Lovings; R H Freeman; David Gewirtz
Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(7):723-33.
1994: W David Jarvis; A J Turner; Lawrence F Povirk; R S Traylor; Steven Grant
Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C.
Cancer research 1994;54(7):1707-14.
1994: W David Jarvis; Lawrence F Povirk; A J Turner; R S Traylor; David Gewirtz; George R Pettit; Steven Grant
Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells.
Biochemical pharmacology 1994;47(5):839-52.
1994: Steven Grant; R Traylor; George R Pettit; P S Lin
The macrocyclic lactone protein kinase C activator, bryostatin 1, either alone, or in conjunction with recombinant murine granulocyte-macrophage colony-stimulating factor, protects Balb/c and C3H/HeN mice from the lethal in vivo effects of ionizing radiation.
Blood 1994;83(3):663-7.
1994: W David Jarvis; Richard Kolesnick; FA Fornari; R S Traylor; David Gewirtz; Steven Grant
Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(1):73-7.
1994: Steven Grant; A J Turner; T M Bartimole; P A Nelms; V C Joe; W David Jarvis
Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
Oncology research 1994;6(2):87-99.
1994: K E Woods; Steven Grant; Saul Yanovich; David Gewirtz
Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin.
Cancer chemotherapy and pharmacology 1994;33(6):509-14.
1993: Steven Grant; R Traylor; George R Pettit; P S Lin
Modulation by bryostatin 1 of the in vitro radioprotective effects of the GM-CSF/IL-3 fusion protein, PIXY 321, on normal human myeloid progenitors.
Cytokine 1993;5(5):490-7.
1993: C W McCrady; F Li; George R Pettit; Steven Grant
Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.
Experimental hematology 1993;21(7):893-900.
1992: Steven Grant; W David Jarvis; Paul Steven Swerdlow; A J Turner; R S Traylor; H J Wallace; P S Lin; George R Pettit; David Gewirtz
Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
Cancer research 1992;52(22):6270-8.
1992: F Li; Steven Grant; George R Pettit; C W McCrady
Bryostatin 1 modulates the proliferation and lineage commitment of human myeloid progenitor cells exposed to recombinant interleukin-3 and recombinant granulocyte-macrophage colony-stimulating factor.
Blood 1992;80(10):2495-502.
1992: Steven Grant; W David Jarvis; A J Turner; H J Wallace; George R Pettit
Effects of bryostatin 1 and rGM-CSF on the metabolism of 1-beta-D-arabinofuranosylcytosine in human leukaemic myeloblasts.
British journal of haematology 1992;82(3):522-8.
1992: Steven Grant; R Traylor; Kapil N Bhalla; C McCrady; George R Pettit
Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells.
Leukemia 1992;6(5):432-9.
1992: Lawrence Boise; Steven Grant; E H Westin
Altered expression of cell cycle related genes including c-myb in a subclone of HL-60 that exhibits reversible differentiation.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1992;3(1):53-61.
1991: Steven Grant; L Boise; E Westin; C Howe; George R Pettit; A Turner; C McCrady
In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Biochemical pharmacology 1991;42(4):853-67.
1991: Steven Grant; George R Pettit; C Howe; C McCrady
Effect of the protein kinase C activating agent bryostatin 1 on the clonogenic response of leukemic blast progenitors to recombinant granulocyte-macrophage colony-stimulating factor.
Leukemia 1991;5(5):392-8.
1991: Steven Grant; Z Arlin; David Gewirtz; E Feldman
Effect of pharmacologically relevant concentrations of mitoxantrone on the in vitro growth of leukemic blast progenitors.
Leukemia 1991;5(4):336-9.
1991: Steven Grant; Kapil N Bhalla; C McCrady
Effect of tetrahydrouridine and deoxytetrahydrouridine on the interaction between 2'-deoxycytidine and 1-beta-D-arabinofuranosylcytosine in human leukemia cells.
Leukemia research 1991;15(4):205-13.
1991: C W McCrady; Joan G Staniswalis; George R Pettit; C Howe; Steven Grant
Effect of pharmacologic manipulation of protein kinase C by phorbol dibutyrate and bryostatin 1 on the clonogenic response of human granulocyte-macrophage progenitors to recombinant GM-CSF.
British journal of haematology 1991;77(1):5-15.
1990: Steven Grant; C Howe; T Kuczynski
Selective eradication of leukemic (L-CFU) versus normal (CFU-GM) myeloid progenitors in suspension culture utilizing a prolonged exposure to 1-B-D arabinofuranosylcytosine (Ara-C) and deoxycytidine (dCyd).
Progress in clinical and biological research 1990;333():69-77.
1990: Steven Grant; Kapil N Bhalla; Z Arlin; C W Howe
The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
Experimental hematology 1990;18(1):41-8.
1990: Steven Grant
Biochemical modulation of cytosine arabinoside.
Pharmacology & therapeutics 1990;48(1):29-44.